Effect of HPV Integration on Prognosis of Young Women With CIN2 in China

Inclusion Criteria: * Female, 18 years of age or older and 45 years of age or younger, with a desire to conceive; * Diagnosed with HSIL (CIN2) or HSIL (CIN2-3) via cervical tissue biopsy within the past 3 months, and has not undergone cervical surgery, physical, or medication treatment; * The lesion area under colposcopy is less than 50% of the total cervical area within the past 3 months; * Plans for 12-month follow-up observation for CIN2, with no surgical, physical, or medication treatment if the disease does not progress; * Understands and voluntarily agrees to participate in the 12-month follow-up of this study, and signs the informed consent form. Exclusion Criteria: * Cervical status at the time of enrollment as determined by colposcopy within the past three months is Type III transformation zone; * Pregnant or lactating; * History of malignant reproductive tract tumors; * History of hysterectomy, cervical surgery, or pelvic radiation therapy; * Physical therapy to the cervix within 24 months prior to enrollment; * The subject has a severe immune system disease that is active; * Long-term use of contraceptives within 12 months prior to enrollment; * Vaginal medication or irrigation within 72 hours prior to sampling (can re-enroll for sampling 3 days after cessation); * Sexual intercourse within 24 hours prior to sampling (can re-enroll for sampling 24 hours after cessation); * Received treatment for genital tract infections, HPV, or other STD pathogens within the past month (can re-enroll one month after cessation of treatment); * Used antibiotics or vaginal microecological improvement products within the past month (can re-enroll one month after cessation of use);